Importantly, our EV engineering platform robustly achieved complete remission in up to 67% of model mice with highly aggressive melanoma when engineered EVs were loaded with the immunostimulatory co‐receptor Ox40L mRNA and injected intratumorally. This evidence concerns the gene TNFSF4 and melanoma.